<DOC>
	<DOCNO>NCT00006262</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness rebeccamycin analogue treat patient refractory stage III stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Rebeccamycin Analogue Treating Patients With Refractory Stage III Stage IV Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate rebeccamycin analogue patient refractory stage III IV ovarian epithelial cancer fail platinum combination paclitaxel chemotherapy . II . Determine toxicities treatment regimen patient . OUTLINE : Patients receive rebeccamycin analogue IV 60 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients complete response receive 3 course receive 3-6 additional course . Patients partial response stable disease receive 3 course receive 3-12 additional course . Patients complete response follow every 2 month 2 year , every 3 month thereafter . All patient follow every 3 month . PROJECTED ACCRUAL : A total 18-39 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III IV ovarian epithelial cancer Platinum resistant disease define disease progression within 6 month receive prior paclitaxel combine cisplatin carboplatin No elevate CA125 evidence disease recurrence Measurable disease At least 20 mm diameter conventional technique OR At least 10 mm diameter spiral CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST ALT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance great 60 mL/min Other : No history allergic reaction compound similar chemical biologic composition rebeccamycin analogue No prior cancer within past 5 year except nonmelanomatous skin cancer No medical problem would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent therapeutic agent cancer</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>